Open AccessMifepristone in fibroids: Comparative study of safety and efficacy of biweekly dosage vs daily dosage schedule
Author(s) -
Neelofar Shaikh,
Reeti Mehra,
Poonam Goel,
Ravinder Kaur
Publication year - 2021
Publication title -
journal of mid-life health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.423
H-Index - 11
eISSN - 0976-7819
pISSN - 0976-7800
DOI - 10.4103/jmh.jmh_90_20
Subject(s) - mifepristone , medicine , dose , uterine fibroids , myoma , leiomyoma , gynecology , hemoglobin , urology , obstetrics , surgery , uterus , pregnancy , genetics , biology
Leiomyomas are the most prevalent benign tumors of the uterus and are seen more with increasing age. 50 mg biweekly dose was compared with 25 mg daily dose in terms of efficacy and safety in symptomatic women as the biweekly dose maybe an economically better alternative. Two different dosages of mifepristone for medical management of fibroids were compared in terms of efficacy and safety in symptomatic women.